439 related articles for article (PubMed ID: 28571533)
1. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
2. Targeting Cdc42 in cancer.
Arias-Romero LE; Chernoff J
Expert Opin Ther Targets; 2013 Nov; 17(11):1263-73. PubMed ID: 23957315
[TBL] [Abstract][Full Text] [Related]
3. The discovery and maturation of peptide biologics targeting the small G-protein Cdc42: A bioblockade for Ras-driven signaling.
Tetley GJN; Murphy NP; Bonetto S; Ivanova-Berndt G; Revell J; Mott HR; Cooley RN; Owen D
J Biol Chem; 2020 Feb; 295(9):2866-2884. PubMed ID: 31959628
[TBL] [Abstract][Full Text] [Related]
4. Progress in the therapeutic inhibition of Cdc42 signalling.
Murphy NP; Mott HR; Owen D
Biochem Soc Trans; 2021 Jun; 49(3):1443-1456. PubMed ID: 34100887
[TBL] [Abstract][Full Text] [Related]
5. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
6. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.
Xiao XH; Lv LC; Duan J; Wu YM; He SJ; Hu ZZ; Xiong LX
Molecules; 2018 Mar; 23(4):. PubMed ID: 29596304
[TBL] [Abstract][Full Text] [Related]
7. Approaches of targeting Rho GTPases in cancer drug discovery.
Lin Y; Zheng Y
Expert Opin Drug Discov; 2015; 10(9):991-1010. PubMed ID: 26087073
[TBL] [Abstract][Full Text] [Related]
8. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes.
Teramoto H; Malek RL; Behbahani B; Castellone MD; Lee NH; Gutkind JS
Oncogene; 2003 May; 22(17):2689-97. PubMed ID: 12730683
[TBL] [Abstract][Full Text] [Related]
9. Cdc42 in oncogenic transformation, invasion, and tumorigenesis.
Stengel K; Zheng Y
Cell Signal; 2011 Sep; 23(9):1415-23. PubMed ID: 21515363
[TBL] [Abstract][Full Text] [Related]
10. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
11. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
12. Targeting Rac and Cdc42 GTPases in Cancer.
Maldonado MDM; Dharmawardhane S
Cancer Res; 2018 Jun; 78(12):3101-3111. PubMed ID: 29858187
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.
Aguilar BJ; Zhao Y; Zhou H; Huo S; Chen YH; Lu Q
Cancer Biol Ther; 2019; 20(6):740-749. PubMed ID: 30849276
[TBL] [Abstract][Full Text] [Related]
14. Emerging strategies to target RAS signaling in human cancer therapy.
Chen K; Zhang Y; Qian L; Wang P
J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
[TBL] [Abstract][Full Text] [Related]
15. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
16. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
17. Rho GTPases: promising cellular targets for novel anticancer drugs.
Fritz G; Kaina B
Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
[TBL] [Abstract][Full Text] [Related]
18. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
Yan C; Theodorescu D
Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
[TBL] [Abstract][Full Text] [Related]
19. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
20. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
